Overview

Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Systemic sclerosis is a multisystem disease and can involve the lungs in the form of ILD. Lung involvement is the most common cause of death in these patients. The present study is performed to study the efficacy of oral mycophenolate mofetil in treating early and mild ILD in patients of SSc. The efficacy and side effects of mycophenolate mofetil will be compared with that of oral placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research
Treatments:
Mycophenolate mofetil
Mycophenolic Acid